Cobomarsen is primarily used in the field of medical research and oncology. It functions as an inhibitor of microRNA-155, which is often overexpressed in certain cancers, including lymphoma and leukemia. By targeting this specific microRNA, cobomarsen helps to regulate cell proliferation and survival, making it a potential therapeutic agent for cancer treatment. Clinical trials are ongoing to evaluate its efficacy and safety in patients with hematologic malignancies, particularly in cases where conventional therapies have shown limited success. Additionally, cobomarsen is being studied for its potential role in modulating immune responses and inflammatory diseases, given the involvement of microRNA-155 in immune system regulation. Its application represents a promising approach in precision medicine for targeting specific molecular pathways involved in disease progression.